Fig. 2.

Analyses of effectiveness by etiology (patients with/without post-stroke epilepsy, patients with/without BTRE, and patients with/without TBIE) at baseline: a  ≥ 50% seizure reduction (mFAS), b seizure freedom (FAS), c continuous seizure freedom (FAS), and d BRV retention (FAS). n represents the number of patients with data for the reported variable at each visit. Patients with missing data were excluded from all seizure analyses. Patients with missing data after BRV discontinuation were considered non-responders and not seizure free. BRV brivaracetam, BTRE brain tumor–related epilepsy, FAS full analysis set, mFAS modified full analysis set, TBIE traumatic brain injury–related epilepsy